• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Quviviq (daridorexant) tablets

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Quviviq (daridorexant) tablets

  • Profile

Profile

Contact Information

Contact: Idorsia Pharmaceuticals
Website: https://www.quviviq.com/s/

Currently Enrolling Trials

    Show More

    General Information

    Quviviq (daridorexant) is an orexin receptor antagonist.

    Quviviq is specifically indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Quviviq is supplied as tablets for oral administration. The recommended dosage is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening.

    Time to sleep onset may be delayed if taken with or soon after a meal.

    In patients with moderate hepatic impairment the maximum recommended dosage is 25 mg no more than once per night. In patients with severe hepatic impairment Quviviq is not recommended.

    Mechanism of Action

    The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

    Side Effects

    Adverse effects associated with the use of Quviviq may include, but are not limited to, the following:

    • headache
    • somnolence or fatigue

    Clinical Trial Results

    The efficacy of Quviviq was evaluated in two multicenter, randomized, double-blind, placebo-controlled, parallel-group studies, Study 1 and Study 2. and 

    A total of 1,854 patients with insomnia according to DSM-5 were randomized to receive Quviviq or placebo once daily, in the evening, for 3 months. Study 1 equally randomized 930 subjects to Quviviq 50 mg, 25 mg or placebo. Study 2 equally randomized 924 subjects to Quviviq 25 mg, 10 mg or placebo. At the end of the 3-month treatment period, both studies included a 7-day placebo run-out period, after which patients could enter a 9-month, double-blind, placebo-controlled extension study. A total of 600 subjects were treated for at least 6 months of cumulative treatment, including 373 treated for at least 12 months. Primary efficacy endpoints for both studies were the change from baseline to Month 1 and Month 3 in Latency to Persistent Sleep (LPS) and Wake After Sleep Onset (WASO), measured objectively by polysomnography in a sleep laboratory. LPS is a measure of sleep induction and WASO is a measure of sleep maintenance.

    In Study 1, doses of 25 and 50 mg Quviviq showed a statistically significant improvement versus placebo on LPS and WASO and self-reported total sleep (sTST), at Month 1 and Month 3. In Study 2, Quviviq 25 mg showed a statistically significant improvement versus placebo on WASO and sTST at Month 1 and Month 3. Quviviq 10 mg did not show a statistically significant improvement on LPS, WASO, or sTST at Month 1 or Month 3. 

    The 50 mg dose of Quviviq also demonstrated significant reduction in daytime sleepiness compared to placebo, as measured by the sleepiness domain score from the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)7 at month 1 and month 3, a key secondary endpoint.

    Approval Date: 2022-01-01
    Company Name: Idorsia Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing